Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $15.09, but opened at $14.64. HUTCHMED shares last traded at $14.70, with a volume of 6,976 shares.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
Get Our Latest Research Report on HUTCHMED
HUTCHMED Stock Performance
The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The stock's 50-day moving average is $14.76 and its two-hundred day moving average is $16.42.
Institutional Trading of HUTCHMED
Large investors have recently modified their holdings of the company. Point72 Hong Kong Ltd bought a new position in HUTCHMED in the third quarter valued at about $421,000. State Street Corp lifted its stake in shares of HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after purchasing an additional 3,078 shares during the period. Jane Street Group LLC boosted its holdings in shares of HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after buying an additional 49,366 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in HUTCHMED during the third quarter valued at approximately $35,000. Finally, Crossmark Global Holdings Inc. grew its position in HUTCHMED by 10.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after buying an additional 1,799 shares during the period. Institutional investors own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
